An interventional study of Lidocaine Hydrochloride 2% Injection Solution and Dexamethasone 4 Mg/mL Injectable Solution in Lumbar Disc Herniation With Radiculopathy, sponsored by Gaziler Physical Medicine and Rehabilitation Education and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Gaziler Physical Medicine and Rehabilitation Education and Research Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Radiculopathy with a site in Turkey — 16 open to participants now, 19 under way, none of them phase 3. Radiculopathy · Turkey.
Among the 59 studies in Radiculopathy with a site in Turkey, this one is the 31st largest by enrollment of the 33 interventional ones that give a count, is one of 12 that started in 2025, is one of 30 with no phase, and was the 53rd registered.
484 studies on the registry are indexed under Radiculopathy; 144 are open to participants now.
Browse Radiculopathy studies →16 of the 59 studies in Radiculopathy with a site in Turkey are open now. Recruiting first, the newest first:
Ankara City Hospital Bilkent · Sites in Turkey
Marmara University · Sites in Turkey
Ages 18 mo+
Alİ Eman, MD · Sites in Turkey
Ages 18–55
Izmir City Hospital · Sites in Turkey
Ages 18–65
Necmettin Erbakan University · Sites in Turkey
Ages 18–70
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 79 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 48 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 60 across 374 interventional studies indexed under Radiculopathy.
Median enrollment 60 across the 33 interventional studies, 114 across the 26 observational. Of the 33 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 59 have an industry lead sponsor. The 10 most frequent:
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital is the lead sponsor of 85 studies on the registry; 14 are open to participants now.
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital has 2 studies filed under Radiculopathy — fewer than ten, so there is no comparison to draw.
5 of the studies in Radiculopathy with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07776431Marmara UniversityElectrophysiological Predictors of Cervical DRG Pulsed Radiofrequency Outcomes | 2026-11 |
| NCT07823426Ankara City Hospital BilkentCervical Spinal Cord Signal Abnormalities in Patients With Cervical Radicular Pain | 2027-02-28 |
| NCT07799142Marmara UniversityFemoral Stretch Test in L2-L4 Lumbar Radiculopathy | 2027-03 |
| NCT07400068Mersin UniversityPLDD With or Without Transforaminal Epidural Steroid Injection in Lumbar Disc Herniation | 2027-04-01 |
| NCT07787741Alİ Eman, MDCervical Epidural Block in Chronic Neck Pain | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 59 studies in Radiculopathy with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to compare the effects of different ultrasound-guided periradicular injection solutions in patients with chronic unilateral radicular pain caused by a single-level lumbar disc herniation.
Participants receive an ultrasound-guided periradicular injection containing lidocaine and dexamethasone, either alone or combined with 5% dextrose or 0.9% sodium chloride. The study evaluates whether adding dextrose or sodium chloride provides additional benefit in reducing pain and improving function and quality of life.
Pain intensity, disability, quality of life, and analgesic use are assessed before treatment and during follow-up. The main hypothesis is that the addition of 5% dextrose or 0.9% sodium chloride may improve the clinical effectiveness of the injection compared with lidocaine and dexamethasone alone.
The aim of this study is to evaluate whether the addition of 5% dextrose or 0.9% sodium chloride to a corticosteroid and local anesthetic solution provides additional benefit in patients with unilateral radicular pain due to single-level lumbar disc herniation. The study also evaluates whether these solutions may facilitate separation of the disc material and surrounding soft tissues from the affected nerve root and whether dextrose provides an additional analgesic effect in relieving radicular pain.
The study was designed as a randomized, controlled, prospective, single-blind clinical trial. A total of 33 patients aged 25-65 years with chronic low back pain resistant to conservative treatment and unilateral radicular leg pain, with single-level lumbar disc herniation confirmed by physical examination and magnetic resonance imaging, were included.
Participants were assigned to treatment groups according to a computer-generated randomization scheme. With n = 11 participants in each group, the first group received a total of 3 mL consisting of 1 mL of 0.2% lidocaine hydrochloride and 8 mg/2 mL of dexamethasone. The second group received a total of 10 mL consisting of 1 mL of 0.2% lidocaine hydrochloride, 8 mg/2 mL of dexamethasone, and 7 mL of 5% dextrose. The third group received a total of 10 mL consisting of 1 mL of 0.2% lidocaine hydrochloride, 8 mg/2 mL of dexamethasone, and 7 mL of 0.9% sodium chloride solution.
Participants were unaware of their assigned treatment group. In all participants, injections were administered under sterile conditions in the outpatient interventional procedure room with the participant in the prone position. All procedures were performed under ultrasound guidance using a 1-5 MHz convex probe as a single-session, unilateral, single-level periradicular injection.
Participants were evaluated at four time points: before the injection, 1 hour after the injection, and during face-to-face follow-up visits at 1 and 3 months. The primary outcome measure was pain intensity assessed using the Visual Analog Scale (VAS). Secondary outcome measures included the Oswestry Disability Index (ODI), the Short Form-36, and the amount of analgesic use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single ultrasound-guided periradicular injection containing 1 mL of 0.2% lidocaine hydrochloride and 8 mg/2 mL dexamethasone.
Drug: Lidocaine Hydrochloride 2% Injection Solution · Drug: Dexamethasone 4 Mg/mL Injectable Solution
Participants receive a single ultrasound-guided periradicular injection containing 1 mL of 0.2% lidocaine hydrochloride, 8 mg/2 mL dexamethasone, and 7 mL 5% dextrose.
Drug: Lidocaine Hydrochloride 2% Injection Solution · Drug: Dexamethasone 4 Mg/mL Injectable Solution · Drug: Dextrose 5% Injection
Participants receive a single ultrasound-guided periradicular injection containing 1 mL of 0.2% lidocaine hydrochloride, 8 mg/2 mL dexamethasone, and 7 mL 0.9% sodium chloride.
Drug: Lidocaine Hydrochloride 2% Injection Solution · Drug: Dexamethasone 4 Mg/mL Injectable Solution · Drug: Sodium Chloride 0.9% Injection Solution
1 mL of lidocaine hydrochloride 20 mg/mL (2%) injection solution was administered as a component of the ultrasound-guided periradicular injection.
Also known as: Jetokain Simplex 20 mg/mL
Drug page: Dexamethasone
2 mL of dexamethasone 4 mg/mL injection solution (total dose: 8 mg) was administered as a component of the ultrasound-guided periradicular injection.
Also known as: Dekort 8 mg/2 mL
7 mL of 5% dextrose solution was administered as a component of the ultrasound-guided periradicular injection.
Also known as: POLİFLEKS 5% Dextrose 100 mL
7 mL of 0.9% sodium chloride solution was administered as a component of the ultrasound-guided periradicular injection.
Also known as: POLİFLEKS 0.9% Sodium Chloride 100 mL Solution for Infusion
Change in Leg Pain Intensity Assessed by Visual Analog Scale (VAS)
Leg pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS), with scores ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. The change in VAS score from baseline will be evaluated at 1 hour, 1 month, and 3 months after the intervention.
Time frame: Baseline, 1 hour, 1 month, and 3 months after the intervention
Change in Low Back Pain Intensity Assessed by Visual Analog Scale (VAS)
Low back pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS), with scores ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. The change in VAS score from baseline will be evaluated at 1 hour, 1 month, and 3 months after the intervention.
Time frame: Baseline, 1 hour, 1 month, and 3 months after the intervention
Change in Disability Assessed by the Oswestry Disability Index (ODI)
Disability related to low back pain will be assessed using the Oswestry Disability Index (ODI). The ODI consists of 10 sections, each scored from 0 to 5, with a total raw score ranging from 0 to 50. The total score is converted to a percentage, ranging from 0% to 100%, where higher scores indicate greater disability. The change in ODI score from baseline will be evaluated during follow-up.
Time frame: Baseline, 1 month, and 3 months after the intervention
Change in Health-Related Quality of Life Assessed by the 36-Item Short Form Health Survey (SF-36)
Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). The questionnaire evaluates eight health domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored from 0 to 100, with higher scores indicating better health-related quality of life. Changes in SF-36 domain scores from baseline will be evaluated during follow-up.
Time frame: Baseline, 1 month, and 3 months after the intervention
Change in Analgesic Medication Use
Analgesic medication use during the previous month will be recorded as the number of days of analgesic use multiplied by the number of analgesic doses taken per day (days × doses). Changes in analgesic medication use from baseline will be evaluated during follow-up.
Time frame: Baseline, 1 month, and 3 months after the intervention
Plan to share: No — Individual participant data will not be shared due to participant confidentiality and data protection considerations.
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Sep 2026, 13 months.
Of 204 non-industry interventional studies with no phase under Radiculopathy, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 13 months is above that.
Counting every sponsor, half of 216 studies reached it within 12 months; a quarter within 5 and three quarters within 45.
Start moved once since we started tracking on Sep 25, 2026: May 2025 → Jul 2025, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glucose · Sodium Chloride
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital